NARCAN Multipacks Approved to Boost Opioid Overdose Response

GAITHERSBURG, MD – February 12, 2026 – In a move aimed at bolstering the nation's response to the opioid crisis, the U.S. Food and Drug Administration (FDA) has approved new multipack configurations for Emergent BioSolutions' over-the-counter (OTC) NARCAN® Nasal Spray. The approval, announced today, introduces 6-count and 24-count packages of the life-saving medication, specifically designed to enhance the efficiency and cost-effectiveness of distribution for organizations on the front lines.

This development comes as the United States continues to grapple with staggering numbers of overdose fatalities, even amid recent signs of progress. The new formats are intended to directly address logistical hurdles faced by community programs, first responders, and public health agencies that distribute naloxone—the active ingredient in NARCAN—in high volumes.

“The introduction of NARCAN® Nasal Spray multipacks marks a significant step in empowering our partners on the front lines,” said Paul Williams, a senior vice president at Emergent, in a statement. He noted the goal is to help them “streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication.”

The Battle for Accessibility

While provisional data from the Centers for Disease Control and Prevention (CDC) suggests a potential decline in annual overdose deaths for the first time since 2018, the crisis remains acute. With fentanyl and other potent synthetic opioids continuing to drive fatalities, rapid access to naloxone is more critical than ever. Overdose remains a leading cause of death for Americans aged 18 to 44.

For years, public health advocates and harm reduction organizations have cited cost and logistical complexity as significant barriers to saturating communities with naloxone. These groups often operate on limited grant funding and rely on volunteers to assemble overdose reversal kits. The process of procuring and managing thousands of individual two-dose boxes can be a major administrative burden.

According to one public health program manager who spoke on the condition of anonymity, “Every dollar and every minute we spend on unpacking boxes and managing inventory is a resource not spent on outreach and training. Larger, bulk packaging could fundamentally change our operational capacity, allowing us to get more naloxone out the door, faster.”

The U.S. naloxone market is projected to more than double by 2032, reflecting sustained demand. Initiatives from agencies like the Substance Abuse and Mental Health Services Administration (SAMHSA) have dramatically increased the number of naloxone kits distributed through funded programs, but challenges of equitable access, stigma, and supply chain efficiency persist.

A Strategic Move in a Competitive Market

The FDA's approval is not just a public health development; it is also a significant strategic move for Emergent BioSolutions. Since NARCAN became the first FDA-approved OTC naloxone nasal spray, the market has grown more competitive. The introduction of RiVive, a 3 mg naloxone spray from the non-profit Harm Reduction Therapeutics, and other generic options has intensified the need for market differentiation.

By targeting the bulk procurement segment, Emergent aims to solidify its relationship with its largest customers: government agencies, hospitals, and community programs. Historically, these non-retail settings have accounted for over 80% of naloxone unit sales. The new 6-count and 24-count multipacks are designed to make NARCAN the most convenient and efficient option for these high-volume partners.

These new configurations will be made available through NARCANDirect®, Emergent’s proprietary ordering platform for public interest customers. This direct-to-partner model allows the company to cater specifically to the needs of institutional buyers, creating a strong foothold in a crucial segment of the market that may be less price-sensitive and more focused on logistical efficiency and reliability.

This strategy complements the company's broader efforts to enhance the product's usability, following the FDA's approval of a NARCAN Nasal Spray Carrying Case in January 2026. Together, these innovations paint a picture of a company working to maintain its brand leadership by addressing the practical, real-world needs of both individual carriers and large-scale distributors.

Streamlining the Frontline Response

For organizations on the ground, the benefits of multipacks extend beyond simple cost savings. Streamlined logistics can have a direct impact on their ability to save lives. First responder agencies can more quickly restock ambulances and supply patrol officers. Community health workers can more easily assemble overdose reversal kits, which often include gloves, a breathing barrier, and educational materials alongside two doses of naloxone.

“In an emergency, efficiency is everything,” commented a veteran paramedic. “Being able to grab a single, larger pack to restock a vehicle, rather than fumbling with multiple small boxes, simplifies our process and reduces the chance for error. It ensures the life-saving tool is ready when we need it.”

This sentiment is echoed by harm reduction advocates, who see the potential for significantly expanding their reach. With more efficient packaging, volunteers can prepare for outreach events more quickly and distribute a larger number of kits to at-risk individuals and their families. If the per-dose cost is reduced through bulk purchasing, it would allow grant-funded programs to stretch their limited budgets further, a critical advantage for organizations that have previously faced supply shortages and high costs.

A Systemic Shift in National Preparedness

The introduction of these multipacks also reflects a broader evolution in the nation's approach to the opioid crisis. The strategy is shifting from a focus on individual prescriptions to one of systemic, widespread community preparedness, where naloxone is treated as an essential public safety tool, much like a fire extinguisher or a defibrillator.

With standing orders in all 50 states allowing pharmacists to dispense naloxone without a patient-specific prescription, access through retail channels has improved. However, the multipacks target a different, equally vital part of the distribution ecosystem: the community-based networks that get naloxone into the hands of those most likely to witness an overdose. This dual approach—improving both individual OTC access and high-volume community distribution—is essential for creating a comprehensive safety net.

Since its initial prescription launch in 2016, over 85 million doses of NARCAN Nasal Spray have been distributed across the U.S. and Canada. The new multipack options, by optimizing the supply chain for those who need it most, represent a critical new tool in the ongoing effort to turn the tide on a public health crisis that has affected every community in the nation.